Timing, Selection, Modulation, and Duration of P2Y
DAPT
P2Y(12) inhibitors
acute coronary syndromes
percutaneous coronary intervention
Journal
JACC. Cardiovascular interventions
ISSN: 1876-7605
Titre abrégé: JACC Cardiovasc Interv
Pays: United States
ID NLM: 101467004
Informations de publication
Date de publication:
09 01 2023
09 01 2023
Historique:
received:
22
08
2022
revised:
03
10
2022
accepted:
10
10
2022
entrez:
4
1
2023
pubmed:
5
1
2023
medline:
7
1
2023
Statut:
ppublish
Résumé
Dual antiplatelet therapy with aspirin and the oral P2Y
Identifiants
pubmed: 36599574
pii: S1936-8798(22)01983-5
doi: 10.1016/j.jcin.2022.10.023
pii:
doi:
Substances chimiques
Platelet Aggregation Inhibitors
0
Purinergic P2Y Receptor Antagonists
0
Prasugrel Hydrochloride
G89JQ59I13
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-18Informations de copyright
Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Funding Support and Author Disclosures Dr Capodanno has received personal fees from Amgen, Arena, Biotronik, Daiichi Sankyo, Sanofi, and Terumo; and has received consulting fees paid to the institution from Medtronic. Dr Angiolillo has received consulting fees or honoraria from Abbott, Amgen, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol Myers Squibb, Chiesi, Daiichi Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, Novartis, PhaseBio, PLx Pharma, Pfizer, Sanofi, and Vectura; and has received institutional payments for grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi Sankyo, Eisai, Eli Lilly, Gilead, Idorsia, Janssen, Matsutani Chemical Industry Co, Merck, Novartis, Osprey Medical, Renal Guard Solutions, and the Scott R. MacKenzie Foundation.